


New screening tool IDs 95% of stage 1 pancreatic cancer

March 21 2022



EV isolation workflows using either Verita™ or ultracentrifugation methods. Credit: *Communications Medicine* (2022). DOI: 10.1038/s43856-022-00088-6

A novel screening platform has flagged more than 95% of stage 1 cancers, according to a pilot study published in *Nature Communications Medicine*. If validated by future studies, the approach offers a new way to detect the third-leading cause of U.S. cancer deaths in 2020.

The study of 139 stage 1 and 2 [cancer patients](#) and 184 controls is the first clinical test of a platform technology called high-conductance di-electrophoresis, developed at Moores Cancer Center at UC San Diego Health 12 years ago. It detects extracellular vesicles (EVs), which contain tumor proteins that are released into circulation by [cancer cells](#)

as part of a poorly understood intercellular communication network. Artificial intelligence-enabled protein marker analysis is then used to predict the likelihood of malignancy.

In addition to detecting 99.5% of stage 1 pancreatic cancers, the approach flagged 74.4% of stage 1 [ovarian cancer](#) and 73.1% of pathologic stage 1A lethally aggressive serous ovarian adenocarcinomas—all with more than 99% specificity—illustrating the potential value of this technology for early [cancer](#) detection.

"The [pancreatic cancer](#) result is particularly promising," said Scott M. Lippman, MD, director of Moores Cancer Center, principal Investigator of the Stand Up To Cancer–Lustgarten Foundation Pancreatic Cancer Interception Dream Team, and co-senior author of the paper. "These results are five times more accurate in detecting early-stage cancer than current liquid biopsy multi-cancer detection tests."

Liquid biopsy tests produce promising results for cancer therapy monitoring and disease relapse, Lippman said, "but they can cause real harm to otherwise healthy people when used for early-disease screening due to unacceptably high false-positive rates that lead to diagnostic tests that are not only expensive, but often dangerous."

Early cancer detection research has yielded tremendous health benefits, Lippman said, resulting in screening methods that detect cancers of the cervix, breast, colon and rectum when they are highly curable. Currently, however, only 5% of [pancreatic cancers](#) are diagnosed in stage 1 and only 10% in time for effective surgery. In 2020, 46,774 Americans died of pancreatic cancer, according to the Centers for Disease Control and Prevention.

"Pancreatic cancer has the lowest five-year relative survival rate of all major cancer killers and is the only one for which both the incidence and

death rates are increasing," said Andrew Lowy, MD, clinical director for Cancer Surgery at UC San Diego Health Moores Cancer Center, and chief of Division of Surgical Oncology at UC San Diego School of Medicine. "Pancreatic cancer is notoriously difficult to detect early, at a stage when surgical resection, the only curative therapy, is possible. At this stage, patients typically have few if any symptoms."

If study results are validated, Lippman said, "we can greatly reduce the mortality from this disease which will soon become the second-leading cause of cancer mortality in the U.S."

More information: Juan Pablo Hinestrosa et al, Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test, *Communications Medicine* (2022). [DOI: 10.1038/s43856-022-00088-6](https://doi.org/10.1038/s43856-022-00088-6)

Provided by University of California - San Diego

Citation: New screening tool IDs 95% of stage 1 pancreatic cancer (2022, March 21) retrieved 4 July 2024 from <https://medicalxpress.com/news/2022-03-screening-tool-ids-stage-pancreatic.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.